Path-specific effects are a broad class of mediated effects from an exposure to an outcome via one or more causal pathways with respect to some subset of intermediate variables. The majority of the literature concerning estimation of mediated effects has focused on parametric models with stringent assumptions regarding unmeasured confounding. We consider semiparametric inference of a path-specific effect when these assumptions are relaxed. In particular, we develop a suite of semiparametric estimators for the effect along a pathway through a mediator, but not some exposure-induced confounder of that mediator. These estimators have different robustness properties, as each depends on different parts of the observed data likelihood. One of our estimators may be viewed as combining the others, because it is locally semiparametric efficient and multiply robust. The latter property is illustrated in a simulation study. We apply our methodology to an HIV study, in which we estimate the effect comparing two drug treatments on a patient's average log CD4 count mediated by the patient's level of adherence, but not by previous experience of toxicity, which is clearly affected by which treatment the patient is assigned to, and may confound the effect of the patient's level of adherence on their virologic outcome.
INTRODUCTION
A literature within causal inference has recently emerged concerning the definition, identification, and estimation of direct and indirect effects in fully nonparametric settings, which includes settings where certain interactions and non-linearities may be present (Robins and Greenland, 1992; Robins, 1999 Robins, , 2003 Pearl, 2001; Avin et al., 2005; Vansteelandt, 2009, 2010; Imai et al., 2010a,b; Shpitser, 2012, 2014) . This strand of work is based on ideas developed by Robins and Greenland (1992) and Pearl (2001) , and uses the language of potential outcomes (Rubin, 1974; Splawa-Neyman et al., 1990) to give a nonparametric definition of effects involved in mediation analysis.
Path-specific effects belong to a large class of mediated effects that capture the effect of an exposure, A, on a post-treatment outcome, Y , through one or more causal pathways, which in- is known as the natural indirect effect, and the causal pathway not through M is known as the pure (or natural) direct effect. Identification and inference corresponding to causal mediation queries in this graph is for the most part resolved (Robins and Greenland, 1992; Pearl, 2001; Petersen et al., 2006; van der Laan and Petersen, 2008; Robins and Richardson, 2010; Shpitser, 2012, 2014) .
More recently, causal mediation analysis grounded in the counterfactual framework has considered tools for other mediated effects of interest. In the present work, we are concerned with the considerably more challenging setting in Fig. 1 .b, in which there is another intermediate variable, C 1 , subsequent to A, but occurring before M and Y . This variable may be affected directly by A, and may in turn confound the effect of M on Y , which has been shown to render certain mediated effects nonparametrically unidentifiable (Shpitser, 2013) . Further, the presence of the gray bi-directed edges between C 0 , C 1 , and Y represent potential unmeasured confounding. We are interested in estimating the path-specific effect along the emboldened pathway A → M → Y , which we term P AM Y . This effect captures the effect of A on Y mediated by M through mechanisms by which A affects M other than those governed by C 1 . In Miles et al. (2017) , we considered an HIV example in which P AM Y is of substantive interest. There, A was an indicator of assignment to one first-line antiretroviral therapy treatment vs. another, C 1 was a measure of adherence and toxicity over the next six months, M was adherence over the subsequent six months, and Y was an indicator of virological failure. Here, we will consider the same setting with CD4 count as outcome. Avin et al. (2005) and Shpitser (2013) have considered general identification conditions for path-specific effects. In Miles et al. (2017) , we presented conditions for identification in the presence of unmeasured confounding, and developed a maximum likelihood estimator of this effect. In this paper, we build on this previous work, and develop semiparametric estimation theory for this effect, allowing for other parts of the likelihood to remain unrestricted. We derive the efficient influence function of the identifying functional for P AM Y , and present a suite of semiparametric estimators with different robustness properties, as each depends on different parts of the observed data likelihood. One of these may be viewed as combining the others, because it is locally semiparametric efficient and multiply robust. By multiply robust, we mean that while this estimator depends on estimation of four nuisance parameters, it remains consistent and asymptotically normal provided only one of three possible subsets of these nuisance parameters are consistently estimated.
DEFINITION AND IDENTIFICATION FORMULA
Suppose that one has observed independent and identically distributed realizations of O = (C 0 , A, C 1 , M, Y ). In the HIV application, A indicates the exposure to one of two first-line antiretroviral therapy treatments prescribed to most HIV patients in Nigeria. For notational convenience, we will use A = a to denote the reference level treatment and A = a to denote the comparison level treatment. The variable C 1 contains a measure of toxicity due to exposure to a particular treatment regimen, ascertained six months after treatment initiation, M is the adherence level during the subsequent six months, Y is the patient's log CD4 count at the end of the year, and C 0 is the vector of all baseline covariates. Letting supp(·) denote the support of its argument, we make the following positivity assumptions (Robins, 1986) :
To formalize the path-specific effect of interest, we now introduce counterfactuals (or potential outcomes). Let Y (a * ) denote a subject's outcome if treatment A were set, possibly contrary to fact, to a * ∈ {a , a}. In the context of mediation, there will also be potential outcomes for the
analogously. We adopt a standard set of consistency assumptions, which link these counterfactuals to the observed variables. Generally, for a set of variables W 1 and a variable W 2 for which the counterfactual W 2 (w 1 ) is defined, if W 1 = w 1 , then W 2 (w 1 ) = W 2 almost everywhere.
We further assume that nested counterfactuals are well defined. The path-specific effect of A on Y along the path A → M → Y , with respect to comparison treatment value a and baseline value a on the mean difference scale is formally defined in terms of the difference in expectations of two nested counterfactuals:
The second term reduces to E{Y (a )}, i.e., the average outcome a patient would have experienced had they been assigned the baseline-value exposure. This term is identified under the no unobserved confounding condition, Y (a )⊥ ⊥A | C 0 , which holds under both graphs in Fig. 1 , and its estimation has been studied extensively (see Rubin (1978) ; Rosenbaum and Rubin (1983) ; Rosenbaum (1984) ; ). As such, the remainder of our discussion will focus on the first term, which we denote
. This term defines the average outcome a patient would experience under an intervention which assigns the patient to the reference-level exposure a , while experiencing the toxicity associated with this exposure, C 1 (a ), however with adherence profile associated with the comparison-level exposure and toxicity profile associated with reference-level treatment, M {a, C 1 (a )}.
In general, it is possible to give an inductive definition of a path-specific effect of A on Y for an arbitrary bundle of pathways, which results in a quantity that is a function of a nested potential outcome. A general definition for the static treatment and single outcome case is given in Pearl 
under independences which hold in a relaxation of the Markovian model represented by the graph in Fig. 1 .b, i.e., in a model where there is no unmeasured confounding of the exposure-outcome and mediator-outcome relationships. A detailed discussion of the causal assumptions implied by this model can be found in that paper.
MAXIMUM LIKELIHOOD ESTIMATION
Thus far, we have considered identification under a nonparametric statistical model, M np , for the observed data, making our identifying functional of P AM Y valid under any possible model for the data satisfying the given positivity conditions. However, because inference in M np is often impractical in situations with numerous confounders (C 0 , C 1 ) relative to sample size (Robins et al., 1997) , we will often be unable to estimate P AM Y nonparametrically, and instead must posit parametric models.
We now consider the first of our four estimators for β 0 . By considering the identifying functional (1) as four nested expectations, it is clear that we can fit three appropriate regression models with parameters γ 1 , γ 2 , and γ 3 using maximum likelihood, and obtain a substitution estimator by plugging the predicted means under these models into the functional; the outermost mean can then be estimated empirically. Thus, the maximum likelihood estimator iŝ
where P n denotes the empirical mean. Inference can be conducted using standard maximum likelihood theory. This estimator is guaranteed to be consistent only under correct specification of these three models, and can be useful if the propensity score is deemed difficult to model. See Miles et al. (2017) for additional details on maximum likelihood-based inference for β.
SEMIPARAMETRIC INFERENCE

Two semiparametric estimators
, and 1 x (·) to be the indicator function. We consider two estimators based on alternative representations of (1), as shown in the supplementary materials:
Similar to the maximum likelihood estimator, these estimators also involve plugging in estimated regression models. When C 1 or M are continuous, one can avoid estimating their conditional densities by instead estimating their conditional density ratios directly. The conditional density ratios can in fact be estimated using regression models for the exposure because by Bayes' theorem,
For instance, when
One can ensure compatibility between these models by the following procedure. First, specify
which is linear in C 0 and C 1 . Then a compatible logistic model for f (a | C 1 , C 0 ) can be obtained by taking as regressors the union of the linear terms in the logistic model for f (a | C 0 ) and
the linear component δ 0 + δ 1 C 0 , and the above normal model is used for C 1 , then
for an appropriate choice of ζ, and hence this logistic model for f (a | C 1 , C 0 ) will be compatible
It follows thatβ a andβ b will be consistent only if their corresponding plugged-in nuisance parameter estimates are consistently estimated. Specifically,β a is consistent under correctly specified working parametric submodels f W (A | C 0 ; γ 1 ) and M ratio;W (γ 2 ), with the remainder of the likelihood left unrestricted;β b is consistent under correctly specified working parametric
, with the remainder of the likelihood left unrestricted.
The estimatorβ a is an inverse probability of treatment weighted-like estimator, and can be useful if the analyst prefers to leave the conditional distributions of Y and C 1 unrestricted.
The estimatorβ b can be useful if the analyst prefers to leave the conditional distribution of M unrestricted.
Locally efficient estimator
We now propose a locally semiparametric efficient estimator,β mr , that we will refer to as the multiply robust estimator for reasons we will explain. This estimator is derived from an estimating equation involving the efficient influence function of β 0 in M np . The efficient influence function is an extension of the parametric score function to semiparametric and nonparametric models. An asymptotically linear estimator with influence function equal to the efficient influence function in a submodel of M np achieves the minimum asymptotic variance of all regular, asymptotically linear estimators in M np , and is said to be locally semiparametric efficient (Bickel et al., 1998 ).
We present the efficient influence function of M np in the following theorem. Define B(m,
and the asymptotic variance of any regular, asymptotically linear estimator of β 0 in M np can be no smaller than var{EIF(β 0 )}, the semiparametric efficiency bound for M np .
The multiply robust estimator is the M-estimator (or Z-estimator (van der Vaart, 2000)) solving the estimating equation formed by setting the empirical mean of the estimated efficient influence function to zero for β 0 . The estimator is then
It is a function of f M |C 1 ,A,C 0 and f C 1 |A,C 0 only via the conditional density ratios M ratio and C ratio 1
and conditional expectation functions B and B .
All nuisance functions are estimated using low-dimensional parametric working models, which we parametrize with γ = (γ 1 , γ 2 , γ 3 , γ 2 , γ 3 , γ 4 , γ 5 , γ 6 ). In particular, B is estimated under the working model
For model robustness purposes, the conditional expectation function B only requires correct specification in terms of the function of M based on the working model for Y , rather than in terms of the true function B(M, C 1 , a , C 0 ),
only requires correct specification of the function of C 1 based on the working models for M and Y , so that B W (γ 3 | γ 1 , γ 2 ) can be correctly specified regardless of whether B W (γ 1 ) and
Additionally, f A|C 0 is estimated under the working model f
, and M ratio under M ratio;W (γ 6 ). The latter two models can be formulated as in Section 4.1 using Bayes' theorem and the same procedure to ensure model compatibility. To ensure the models for B and B are compatible with these density ratio models, one can use regression models that agree with the models used to obtain f (a | C 1 , C 0 ) and f (a | M, C 1 , C 0 ) in the procedure described in Section 4.1. For instance, if B W (γ 1 ) is linear in M , and one uses the
, then one should use a regression model for B that is linear in C 0 , A, and C 1 .
An attractive property ofβ mr is its robustness to multiple types of model mis-specification.
(γ 5 ) , we give a multiple robustness result in the following theorem.
Theorem 2. The estimatorβ mr is consistent and asymptotically normal (under standard regularity conditions) provided that one of the following holds:
It is locally semiparametric efficient in that it will achieve the semiparametric efficiency bound in the intersection submodel in which (a)-(c) all hold.
Thus,β mr offers three distinct opportunities to obtain a consistent estimator of the pathspecific effect. By contrast,β a will be consistent only if a slightly weaker form of (a) holds, where B W (γ 2 ) need not be correctly specified;β b will be consistent only if a slightly weaker form of (b) holds, where B W (γ 3 ) need not be correctly specified; andβ mle will be consistent only if a slightly weaker form of (c) holds, where M ratio;W (γ 6 ) and C ratio;W 1 (γ 5 ) need not be correctly specified.
For inference onβ mr , we recommend the nonparametric bootstrap (Efron, 1979) or similar alternative resampling methods. While one might consider using an empirical estimator of the efficient influence function variance, it does not have the multiple-robustness property, sinceβ mr is not globally efficient. Thus, this variance estimator may be inconsistent under certain forms of model mis-specification even ifβ mr is still consistent.
While all four estimators given here are in fact asymptotically equivalent under a nonparametric model, they will have different asymptotic properties under parametric and semiparametric models (Tchetgen Tchetgen and Shpitser, 2012) .
Stabilization techniques
Due to the proposed estimators' reliance on inverse-probability weights, they may suffer from instability in settings where the set of positivity assumptions is nearly violated (Kang and Schafer, 2007) . A useful stabilization technique is to simply replace any propensity scoref A|X withf † A|X , where X is some vector of covariates and logitf † Another stabilization technique, based on a procedure proposed by Robins (2000) and detailed in his comment (Robins et al., 2007) in response to Kang and Schafer (2007) , can also be adapted to this setting for the multiply robust estimator. The idea is to obtain a substitution estimator by carefully selecting regression models and an estimation strategy such that the three terms inβ mr depending on weights are empirically evaluated as null, leaving the term P nB (a , a, C 0 ;γ 3 |γ 1 ,γ 2 ), a plug-in term, which does not depend on weights. This can be accomplished by the following procedure.
First, fit propensity score models to obtain estimatesf A|C 0 (γ 4 ),Ĉ ratio 1 (γ 5 ), andM ratio (γ 6 ) as described previously. Next, using these estimates, estimate γ 1 by solving
where B W (γ 1 ) contains an intercept, such that one of the elements in
one. This ensures that the first term in the estimating equation forβ mr is zero atγ. Next, estimate γ 2 by solving
where B W (γ 2 |γ 1 ) contains an intercept, such that one of the elements in ∇ γ 2 B (C 1 , a , C 0 ; γ 2 | γ 1 ) is one. This ensures that the second term in the estimating equation forβ mr is zero atγ. Next, estimate γ 3 by solving
where B W (γ 3 |γ 1 ,γ 2 ) contains an intercept, such that one of the elements in ∇ γ 3 B (a , C 0 ; γ 3 | 
(C 1 , C 0 ;γ 5 )}, and 1 a (A)/f (a | C 0 ;γ 1 ), respectively.
This latter stabilized estimator matches the targeted minimum-loss based estimator (van der Laan and Rubin, 2006) for a particular choice of submodels and loss functions. For example, if linear models are used for B, B , and B , then the estimator described above corresponds to a targeted minimum loss-based estimator using squared-error loss functions for B, B , and B , submodels
(1, C 0 ) 3 , and using initial estimates B 0 (C 0 , C 1 , M ) = B 0 (C 0 , C 1 ) = B 0 (C 0 ) = 0.
SIMULATION STUDY
We conducted a simulation study in order to demonstrate the finite-sample performance of these estimators as well as the multiple-robustness property ofβ mr . We generated 1000 data sets of size 5000 from the data generating mechanism: are not. The intersection model uses correctly specified working models.
All models were fit by maximum likelihood. The first stabilization technique described in the previous section was used to adjust propensity scores. We used the following working models, subscripted C for correctly specified and I for incorrectly specified, and where Φ denotes the standard normal distribution function:
, which depends on the correctly specified f W A|C 0 model and the correctly specified
, which depends on the correctly specified B W model and the correctly specified models
Incorrect: C ratio;W,I 1
, which depends on the correctly specified f W A|C 0 model and the incorrectly specified model logit pr
, which depends on the incorrectly specified B W model, the correctly specified working mean model for M used for B C (a , a, C 0 ) above, and the incorrectly specified model
is only mis-specified in setting (a), under which B W is also mis-specified and θ W M is correctly specified.
, which depends on the correctly specified model logit pr
M ]γ C and the correctly specified logistic model used for C ratio;W 1 above;
W model and the correctly specified mean model for M used for B C (a , a, C 0 ) above.
, which depends on the correctly specified logistic model for pr C { A = 1 | C 1 , C 0 } and the incorrectly specified model logit pr sponding models where the mis-specified components did not factor into estimation, as expected. 
HARVARD PEPFAR NIGERIA ANALYSIS
We now present results of the Harvard PEPFAR data analysis. The data set consisted of 48,345
observations, 9968 (41.9%) of which were complete observations, i.e., observations with no missing variables. Nonmonotone missingness was handled by multivariate imputation by chained equations (van Buuren and Groothuis-Oudshoorn, 2011).
Our effect of interest is the path-specific effect of treatment regimen assignment on log CD4 count through adherence on the mean difference scale. We estimated β 0 withβ mr and E{Y (a )} with the augmented inverse probability of treatment weighted estimator (Bang and Robins, 2005) .
Comparisons with other estimators are available in the supplementary materials. Results were fairly consistent across estimators. LetP AM Y ;mr denote the effect estimate contrasting these two estimators. We computed this estimate and its corresponding confidence interval using a bootstrap variance estimate for each pairwise comparison of treatments.
We coded the treatment regimens in descending order of magnitude of their total effects on mean log CD4 count. That is, they were coded in ascending order of mean counterfactual CD4 count had everyone been assigned to that treatment, since a lower counterfactual risk of failure corresponds to a higher magnitude of total effect. See Table 1 note for treatment coding.
The order of these effects differed from those on risk of virological failure, so our coding does not correspond directly with that used in Miles et al. (2017) . Because in practice we are more interested in learning how less-effective treatments can be improved, we only consider the highercoded treatment in a pair as the baseline, a .
We are primarily interested in the percentage of the total effect attributable to the mediated effect, i.e., the percent mediated by P AM Y . If this value is close to 100%, we can conclude that the drugs themselves likely have the same effectiveness on CD4 count, and that it is their differential effect on adherence not due to toxicity that is driving the difference in total effects.
If, on the other hand, this percentage is small or negative, we can only say that the difference in total effects is not driven by a difference in effects through P AM Y . It may be the case that the efficacies of the drugs themselves do, in fact, differ, or that the difference in total effects is driven by the differential effect on adherence due to toxicity, but we cannot confirm either. Table   1 shows one hundred timesP AM Y ;mr divided by the total effect estimates, which are also on the mean difference scale and are estimated with the augmented inverse probability of treatment weighted estimator. Treatment comparisons with statistically significant path-specific effects are indicated by asterisks. Due to the treatment coding, the denominators of the Table 1 values are always positive. Thus, a positive path-specific effect will be in the same direction as the total effect, and hence will explain a positive proportion of it.
We estimated a significant path-specific effect in four of the treatment comparisons. In one of these comparisons, the effect estimate was positive; in the other three it was negative. In the latter case, this implies that the percentages of the total effects due to the effects through P AM Y were also negative, since the total effect estimates are positive for each treatment comparison we NOTE: * Significant path-specific effect (α = 0.05). 1 = AZT + 3TC + NVP, 2 = TDF + 3TC/FTC + EFV, 3 = AZT + 3TC + EFV, 4 = d4T + 3TC + NVP, 5 = TDF + 3TC/FTC + NVP. 3TC=lamivudine, AZT=zidovudine, d4T=stavudine, EFV=efavirenz, FTC=emtricitabine, NVP=nevirapine, TDF=tenofovir.
consider. Thus, in these treatment comparisons, the estimated P AM Y path-specific effects and estimated total effects are in opposite directions. Since the total effect can be decomposed as a sum of multiple path-specific effects including the one through P AM Y , this means that the other path-specific effects are, in sum, stronger in the opposite direction than the P AM Y path-specific effect, and overwhelm it to produce a positive total effect. This also means that had there been no effect through P AM Y , the total effect would have been even larger than what we observed, since we would have been adding zero to the other path-specific effects that compose the total effect, rather than a negative value. For example, our findings indicate that the effect of treatment 5, as compared to treatment 4, would have been 54% lower if its impact on adherence via mechanisms other than toxicity (e.g., pill count, meal restrictions, etc.) were the same as that of treatment 4. This would result in an even larger total effect between these treatments.
The path-specific effect comparing treatment 1 to treatment 3, on the other hand, explains a positive proportion (approximately 44%) of the total effect estimate. This means that when assigning treatment 3, if we could intervene to change the the factors affecting later adherence other than early adherence and toxicity to be the same as those the patients would experience under treatment 1 (e.g., the same pill count and meal restrictions as treatment 1), then we would be able to close the gap in effectiveness on log CD4 count between treatments 3 and 1 by about 44%. A final note: the percentage mediated of the effect comparing treatments 3 and 2 is inflated to -103% by virtue of the denominator, i.e., the total effect, being fairly small.
A. THEORETICAL RESULTS
A.1 Derivation of estimators a and b
The estimatorβ a arises from an alternative representation of the identifying functional of β 0 :
We simply plug in the estimates,f E=0|C 0 andM ratio , and compute the empirical mean. Thus, we
The estimatorβ b arises from a second representation of the identifying functional of β 0 :
Again, we plug in the estimatesĈ
, and compute the empirical mean. Thus, we havê
A.2 Proofs
Proof of Theorem 1. Let ν denote the appropriate dominating measure or product measure corresponding to each combination of random variables. Let F O;t = F Y |M,C,E,C 0 ;t F M |C 1 ,E,C 0 ;t F C 1 |E,C 0 ;t F E|C 0 ;t F C 0 ;t denote a one-dimensional regular parametric submodel of M np with F O,0 = F O , and let
and
be the score for O. Then
where {B(M, C 1 , e , C 0 ) − B (C 1 , e , e, C 0 )} + 1 e (E) f (e | C 0 ) {B (C 1 , e , e, C 0 ) − B (e , e, C 0 )} + {B (e , e, C 0 ) − β 0 } ,
B. PLOT COMPARING ESTIMATORS IN PEPFAR ANALYSIS
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e=1, e'=2 e=1, e'=3 e=1, e'=4 e=1, e'=5 Estimator Estimate on difference in mean log CD4 count scale Estimated PSEs on CD4 count Figure 3 : P EM Y path specific effects on CD4 count. The plot in each cell represents estimates for the effect with comparison-level treatment, e, equal to the first index of the cell and baselinelevel treatment, e equal to the second index of the cell. That is, comparison level treatment varies across rows and baseline level treatment varies across columns. Within each plot, the dots and vertical bars represent point estimates using the four estimators and their corresponding bootstrap confidence intervals.
